Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 111-115

  Ford, Monique A ^a   McConnell, Joseph P ^a   Lavi, Shahar ^a   Rihal, Charanjit S ^a   Prasad, Abhiram ^a   Sandhu, Gurpreet S ^a   Hartman, Stacy J ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

Atherosclerosis; Endothelial dysfunction; Lipoprotein particles; Nuclear magnetic resonance spectroscopy

Indexed keywords

ACETYLCHOLINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FEMALE; GENDER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ACETYLCHOLINE; ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROCIRCULATION; MIDDLE AGED; PARTICLE SIZE; VASODILATION; VASODILATOR AGENTS; YOUNG ADULT;

EID: 70350510163     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.039     Document Type: Article

References (35)

1. Ford M., Allison T., and Lerman A. New approaches to the concept of primary prevention of atherosclerosis. Current Treatment Options in Cardiovascular Medicine (2008) 1
2. Lerman A., and Zeiher A.M. Endothelial function: cardiac events. Circulation 111 (2005) 363-368
3. Bonetti P.O., Lerman L.O., and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology 23 (2003) 168-175
4. Cromwell W.C., Otvos J.D., Keyes M.J., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management. Journal of Clinical Lipidology 1 (2007) 583-592
5. Mora S., Szklo M., Otvos J.D., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192 (2007) 211-217
6. El Harchaoui K., van der Steeg W.A., Stroes E.S., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Journal of the American College of Cardiology 49 (2007) 547-553
7. van der Steeg W.A., Holme I., Boekholdt S.M., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. Journal of the American College of Cardiology 51 (2008) 634-642
8. Colhoun H.M., Otvos J.D., Rubens M.B., Taskinen M.R., Underwood S.R., and Fuller J.H. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes 51 (2002) 1949-1956
9. Mackey R.H., Kuller L.H., Sutton-Tyrrell K., Evans R.W., Holubkov R., and Matthews K.A. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. Archives of Internal Medicine 165 (2005) 510-515
10. Kuller L.H., Grandits G., Cohen J.D., Neaton J.D., and Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 195 (2007) 122-128
11. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113 (2006) 20-29
12. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. The American Journal of Cardiology 90 (2002) 89-94
13. Mora S., Otvos J., Buring J.E., and Ridker P.M. A prospective comparison of NMR-measured LDL particle number, apolipoprotein B100, and standard lipids with incident CHD in 27,673 initially healthy women. Circulation 116 (2007) 787-788
14. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clinics in Laboratory Medicine 26 (2006) 847-870
15. Deanfield J., Donald A., Ferri C., et al. Endothelial function and dysfunction. Part I. Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Journal of Hypertension 23 (2005) 7-17
16. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes Jr. D.R., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
18. Kuller L., Arnold A., Tracy R., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arteriosclerosis, Thrombosis, and Vascular Biology 22 (2002) 1175-1180
19. Blake G.J., Otvos J.D., Rifai N., and Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106 (2002) 1930-1937
20. Mackey R.H., Kuller L.H., Sutton-Tyrrell K., Evans R.W., Holubkov R., and Matthews K.A. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. The American Journal of Cardiology 90 (2002) 71i-76i
21. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
22. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 350 (2004) 1495-1504
23. Woodman R.J., Watts G.F., Playford D.A., Best J.D., and Chan D.C. Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes. Diabetes, Obesity & Metabolism 7 (2005) 612-617
24. Anderson T.J., Meredith I.T., Charbonneau F., et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93 (1996) 1647-1650
25. Chait A., Brazg R.L., Tribble D.L., and Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. American Journal of Medicine 94 (1993) 350-356
26. Vakkilainen J., Makimattila S., Seppala-Lindroos A., et al. Endothelial dysfunction in men with small LDL particles. Circulation 102 (2000) 716-721
27. Lavi S., Yang E.H., Prasad A., et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 51 (2008) 127-133
28. Hartman S., Jaffe A.S., and McConnell J.P. Independent evaluation of nuclear magnetic resonance lipoprotein subclass analysis. ACC 2006 (2006)
29. Sirtori C.R., Calabresi L., Pisciotta L., et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutrition, Metabolism, and Cardiovascular Diseases 15 (2005) 47-55
30. Lavi S., Prasad A., Yang E.H., et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 115 (2007) 2621-2627
31. Johansson J., Carlson L.A., Landou C., and Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arteriosclerosis Thrombosis 11 (1991) 174-182
32. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. The New England Journal of Medicine 357 (2007) 2109-2122
33. Vergeer M., Bots M.L., van Leuven S.I., et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118 (2008) 2515-2522
34. Forrest M.J., Bloomfield D., Briscoe R.J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. British Journal of Pharmacology 154 (2008) 1465-1473
35. Hermann F., Enseleit F., Spieker L.E., et al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thrombosis Research 123 (2009) 460-465